CD163 and systemic sclerosis: In cultured SSc-ILD MDMs, nintedanib 0.1 and 1μM significantly downregulated the gene expression and protein synthesis of CD204, CD206, CD163 (p < 0.05), and MerTK (p < 0.01) compared to untreated cells after 24 h of treatment.